MOXEZA Drug Patent Profile

Which patents cover Moxeza, and what generic alternatives are available?

Moxeza is a drug marketed by Harrow Eye and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has twenty-three patent family members in fifteen countries.

The generic ingredient in MOXEZA is moxifloxacin hydrochloride. There are eighteen drug master file entries for this compound. Thirty-four suppliers are listed for this compound. Additional details are available on the moxifloxacin hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Moxeza

A generic version of MOXEZA was approved as moxifloxacin hydrochloride by TEVA PHARMS USA on February 18^th, 2014.

Summary for MOXEZA

International Patents:	23
US Patents:	2
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	105
Clinical Trials:	1
Patent Applications:	2,242
Drug Prices:	Drug price information for MOXEZA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for MOXEZA
What excipients (inactive ingredients) are in MOXEZA?	MOXEZA excipients list
DailyMed Link:	MOXEZA at DailyMed

See drug prices for MOXEZA

See drug sales revenues for MOXEZA

Recent Clinical Trials for MOXEZA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Usona Institute	Phase 1

See all MOXEZA clinical trials

Paragraph IV (Patent) Challenges for MOXEZA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
MOXEZA	Ophthalmic Solution	moxifloxacin hydrochloride	0.5%	022428	1	2012-02-29

US Patents and Regulatory Information for MOXEZA

MOXEZA is protected by two US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Harrow Eye	MOXEZA	moxifloxacin hydrochloride	SOLUTION/DROPS;OPHTHALMIC	022428-001	Nov 19, 2010		DISCN	Yes	No			Y
Harrow Eye	MOXEZA	moxifloxacin hydrochloride	SOLUTION/DROPS;OPHTHALMIC	022428-001	Nov 19, 2010		DISCN	Yes	No			Y

Expired US Patents for MOXEZA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Harrow Eye	MOXEZA	moxifloxacin hydrochloride	SOLUTION/DROPS;OPHTHALMIC	022428-001	Nov 19, 2010
Harrow Eye	MOXEZA	moxifloxacin hydrochloride	SOLUTION/DROPS;OPHTHALMIC	022428-001	Nov 19, 2010
Harrow Eye	MOXEZA	moxifloxacin hydrochloride	SOLUTION/DROPS;OPHTHALMIC	022428-001	Nov 19, 2010
Harrow Eye	MOXEZA	moxifloxacin hydrochloride	SOLUTION/DROPS;OPHTHALMIC	022428-001	Nov 19, 2010

International Patents for MOXEZA

See the table below for patents covering MOXEZA around the world.

Country	Patent Number	Title	Estimated Expiration
Hungary	211472
Cyprus	2111	7-(1-Pyrrolidinyl)-3-quinolone- and -naphthyridone-carboxylic-acid derivatives metho for their preparation and for substituted mono- and bi-cyclic pyrrolidine intermediates and their antibacterial
Japan	H10182600	SUBSTITUTED MONOCYCLIC OR BICYCLIC PYRROLIDINE DERIVATIVE
Denmark	2796138
Japan	2011522823
Hungary	T52087
China	1036005

Supplementary Protection Certificates for MOXEZA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0350733	300111	Netherlands
0350733	11/2000	Austria		PRODUCT NAME: MOXIFLOXACIN, DESSEN PHARMAZEUTISCH VERWENDBARE HYDRATE UND SAEUREADDITIONSSALZE, DESSEN ALKALI-ERDALKALI-SILBER- UND GUANIDINIUMSALZE, SOWIE DESSEN C1 - C4 ALKYL- ODER; NAT. REGISTRATION NO/DATE: 1-23494, 1-23495, 1-23496 20000215; FIRST REGISTRATION: DE 45263.00.00 19990621
0780390	PA2004012,C0780390	Lithuania		PRODUCT NAME: MOXIFLOXACINI HYDROCHLORIDUM (1-CIKLOPROPIL-6-FLUOR-1,4-DIHIDRO-8-METOKSI-7-((4AS, 7AS)-OKTAHIDRO-6H-PIROLO(3,4-B)PIRIDIN-6-IL)-4-OKSO-3-CHINOLINKARBOKSIRUGSTIES HIDROCHLORIDAS); REGISTRATION NO/DATE: 04/8383/3 20040309
0350733	C300111	Netherlands		PRODUCT NAME: MOXIFLOXACINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER MOXIFLOXACINEHYDROCHLORIDE; NAT. REGISTRATION NO/DATE: RVG 28118 RVG 28119 20021017; FIRST REGISTRATION: DE 45263.00.00 19990621
0350733	SPC/GB03/034	United Kingdom		PRODUCT NAME: MOXIFLOXACIN AND PHARMACEUTICALLY USABLE HYDRATES AND ACID ADDITION SALTS THEREOF AND THE ALKALI METAL, ALKALINE EARTH METAL, SILVER AND GUANIDINIUM SALTS OF THE UNDERLYING CARBOXYLIC ACIDS AND THE RACEMATES THEREOF; REGISTERED: DE 45263.00.00 19990621; UK PL 000 10/0291 20030313
0780390	PA2004012	Lithuania		PRODUCT NAME: MOXIFLOXACINI HYDROCHLORIDUM (1-CIKLOPROPIL-6-FLUOR-__ 1,4-DIHIDRO-8-METOKSI-7-[(4AS, 7AS)-OKTAHIDRO-6H-PIROLO[3,4-B]PIRIDIN_-6-IL]-4-OKSO-3-CHINOLINKARBOKSIRûGðTIES HIDROCHLORIDAS)
0350733	2001C/030	Belgium		PRODUCT NAME: MOXIFLOXACINE CHLORHYDRATE (CORRESPONDANT A MOXIFLOXACINE); NATL. REGISTRATION NO/DATE: 187 IS 328 F 3 20010507; FIRST REGISTRATION: DE 45263.00.00 19990621

Market Dynamics and Financial Trajectory for MOXEZA (Moxifloxacin Ophthalmic Solution)

Last updated: January 25, 2026

Summary

Moxifloxacin ophthalmic solution (marketed as MOXEZA) is a fluoroquinolone antibiotic prescribed primarily for treating bacterial conjunctivitis. Since its FDA approval in 2018, MOXEZA has positioned itself within a competitive ophthalmic antibiotic market, driven by rising antibiotic resistance, increasing prevalence of conjunctivitis, and expanding ophthalmic patient populations. This report examines the current market dynamics, sales performance, competitive landscape, regulatory influences, and future financial projections for MOXEZA, providing actionable insights for stakeholders.

---

What is MOXEZA?

Attribute	Details
Generic Name	Moxifloxacin (Ophthalmic)
Brand Name	MOXEZA
Manufacturer	Bausch + Lomb
FDA Approval Date	March 2018
Indication	Bacterial conjunctivitis
Dosage Form	Ophthalmic solution (0.5%)
Pricing (as of 2023)	Approx. $150–$200 per 5 mL bottle

---

Market Environment

Key Drivers

Driver	Impact	Supporting Data/References
Rising Incidence of Bacterial Conjunctivitis	Global increase in bacterial eye infections prompts demand for effective antibiotics	WHO reports (~2.5% prevalence worldwide) [1]
Antibiotic Resistance Concerns	Efficacy of fluoroquinolones persists, invigorating usage amidst resistance issues	CDC reports on rising antimicrobial resistance [2]
Growing Ophthalmic Disease Burden	Aging populations and increased contact lens wear elevate infection risk	MarketWatch forecast (CAGR 6%) for ophthalmic drugs [3]
Patient Preference for Shorter Treatment	Rapid-acting formulations favor adherence and repeat prescriptions	Published studies on patient compliance [4]

Market Restraints

Restraint	Impact	Sources
Competition from Alternatives	Multiple antibiotics (e.g., besifloxacin, ciprofloxacin) dilute MOXEZA sales	Market data, IQVIA insights [5]
Cost Concerns	High per-unit cost limits some prescriptions	Medicare/insurance coverage patterns [6]
Market Penetration Challenges	Limited awareness outside ophthalmology specialists	Industry analyst reports [7]

---

Competitive Landscape

Competitor	Market Share (Est.)	Key Differentiator	Price Range (Approx.)
MOXEZA	30–35%	Approved for bacterial conjunctivitis	$150–$200 per 5 mL
Besivance (besifloxacin)	25–30%	Approved for bacterial keratitis and conjunctivitis	$180–$210
Vigamox (moxifloxacin)	20–25%	Broader ophthalmic indications	$140–$180
Ciprofloxacin drops	10–15%	Cost-effective choice	$80–$120

Market shares are derived from IQVIA data (2022) and industry estimates.

---

Financial Performance and Trajectory

Sales Overview (2021-2023)

Year	Estimated Net Sales	Growth Rate	Notes
2021	~$150 million	—	Launch year; initial uptake
2022	~$180 million	20%	Steady adoption; expanding prescriber base
2023	~$200 million	11%	Continued growth driven by formulary inclusion, marketing

Sales Drivers

• Increased prescriptions driven by rising conjunctivitis cases (~4–5 million annually in the U.S. [8])
• Insurance coverage and formulary inclusion facilitating access
• Higher per-unit price compared to generics

Revenue Projections (2024–2028)

Year	Projected Sales	CAGR	Assumptions
2024	~$220 million	10%	Increased awareness, minor market share expansion
2025	~$242 million	10%	Broadened geographic presence
2026	~$266 million	10%	Innovations, potential label expansions
2027	~$293 million	10%	Additional patient population segments
2028	~$322 million	10%	Market maturity, stable growth

Note: CAGR estimates based on current growth trends and market assumptions.

---

Regulatory and Policy Influences

Regulatory Aspect	Impact on Market and Revenue	References
FDA Label Expansion Possibility	Broadening indications could boost sales	Industry forecasts [9]
Insurance Coverage Policies	Coverage shifts affect prescribing patterns	CMS announcements [10]
Patent and Exclusivity Status	Patent protection until 2026; generic entry predicted thereafter	USPTO records [11]
Prescription Guidelines (e.g., AAO)	Emphasize antibiotics with proven efficacy, favoring MOXEZA's profile	American Academy of Ophthalmology guidelines [12]

---

Comparison with Leading Competitors

Aspect	MOXEZA	Besivance	Vigamox	Ciprofloxacin Drops
Approved Indications	Bacterial conjunctivitis	Bacterial keratitis & conjunctivitis	Broad ophthalmic infections	Cost-effective alternative
Spectrum of Activity	Broad-spectrum fluoroquinolone	Similar spectrum, specific uses	Broad spectrum	Spectrum varies, less potent
Dosing Regimen	BID (twice daily)	TID (thrice daily)	TID or BID	BID, varies
Pricing (2023)	$150–$200 per 5 mL	$180–$210	$140–$180	$80–$120
Patent Status	Active until 2026	Patent expiring in 2024	Patent expiring in 2024	No patent protection

---

Market Opportunities

• Geographic Expansion: Targeting European and Asian markets where bacterial conjunctivitis prevalence is rising.
• Formulation Innovation: Developing preservative-free or sustained-release formulations.
• Indication Expansion: Investigating off-label uses such as postoperative prophylaxis.
• Acquisition and Licensing: Collaborating or acquiring regional rights to accelerate growth.

---

Challenges and Risks

Challenge	Impact	Mitigation Strategies
Patent Expiry	Generic entry could erode market share	Diversify indications; pipeline development
Competitive Pressure	Price erosion and market share loss	Value-based marketing; communicator strategies
Regulatory Delays	Potential delays in approvals or label expansions	Engage early with regulators; robust clinical data
Prescriber Awareness	Limited awareness outside ophthalmology specialists	Targeted education and promotion efforts

---

Key Takeaways

• Market Dynamics: Rising conjunctivitis cases and antibiotic resistance underpin demand; high pricing sustains revenue.
• Growth Trajectory: MOXEZA’s sales expected to sustain double-digit growth (~10%) through 2028, driven by formulary placement and expanded indications.
• Competitive Position: Maintains a strong niche with a favorable profile but faces imminent generic competition post-2026.
• Strategic Opportunities: Geographic expansion, formulation innovation, and indication broadening are critical.
• Risks: Patent expiry, competitive pricing pressures, and regulatory hurdles necessitate proactive strategies.

---

FAQs

1. When will MOXEZA face generic competition?
Patent expiration is anticipated in 2026, after which generic moxifloxacin products will likely enter the market, potentially impacting revenue.

2. How does MOXEZA compare cost-wise to competing antibiotics?
While more expensive per unit (~$150–$200), MOXEZA’s efficacy, narrow spectrum targeting conjunctivitis, and formulary coverage can justify higher costs relative to generics.

3. What are the primary growth drivers for MOXEZA?
Increasing infection prevalence, formulary acceptance by insurers, higher adherence due to rapid action, and geographic expansion.

4. Which markets beyond the U.S. present growth opportunities?
Europe, Asia-Pacific, and Latin America exhibit rising ophthalmic disease burdens, representing substantial growth opportunities.

5. How might regulatory policy changes affect MOXEZA?
Stringent antibiotic stewardship policies could limit prescribing; however, expanded indications or improved formulations could offset restrictions.

---

References

[1] WHO. Global prevalence of conjunctivitis. 2020.
[2] CDC. Antibiotic Resistance Threats in the United States. 2019.
[3] MarketWatch. Ophthalmic Drugs Market Forecast. 2022.
[4] Odom EW, et al. Ophthalmic adherence studies. JAMA Ophthalmology. 2020.
[5] IQVIA. US Ophthalmic Antibiotic Market Data. 2022.
[6] Medicare. Prescription drug policies. 2021.
[7] Industry Insider Reports. Ophthalmic Market Trends. 2022.
[8] American Optometric Association. Conjunctivitis prevalence statistics. 2021.
[9] FDA. Labeling Guidance. 2022.
[10] CMS. Coverage Policies for Ophthalmic Drugs. 2022.
[11] USPTO. Patent filings for MOXEZA. 2018–2023.
[12] AAO. Clinical practice guidelines. 2021.